OR4A21P

Across TCGA pan-cancer cohorts, OR4A21P Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated OR4A21P data layer compared with 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher OR4A21P Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR4A21P expression acts as an unfavorable survival marker.

OV are the cancer types where OR4A21P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.140	0.541	.001	18	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

OR4A21P–OV (DFS)

Open the OV breakdown →